Business Monitor International


Philippines Pharmaceuticals & Healthcare Report

Published 11 June 2014

  • 127 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Philippines Pharmaceuticals & Healthcare Report

BMI View:  The Philippine government's aim to lower pharmaceutical expenditure through medicine price cuts, parallel imports and the use of generic drugs will continue to hinder multinational pharmaceutical firms' investment and interest in the country's pharmaceutical market. Nevertheless, the government's intention to improve healthcare through the implementation of a universal healthcare scheme will continue to present significant revenue-generating opportunities for firms over the long term. 

Headline Expenditure Projections

  • Pharmaceuticals: PHP140.20bn (USD3.25bn) in 2013, rising to PHP145.05bn (USD3.30bn) in 2014; +3.5% in local currency terms and +1.6% in US dollar terms.

  • Healthcare: PHP545.09bn (USD12.62bn) in 2013, rising to PHP613.05bn (USD13.93bn) in 2014; +12.5% in local currency terms and +10.4% in US dollar terms.

Risk/Reward Rating: Out of the 19 pharmaceutical markets assessed in Asia Pacific, the Philippines remains in 14th place (scoring 45.3 out of 100), trailing the regional average in most metrics. In Q414, Japan is ranked as the most attractive market in the Asia Pacific region (scoring 78.1 out of 100), followed by South Korea (68.6) and Australia (65.8).

Key Trends And Developments

In July 2014, the US Food and Drug Administration (FDA) advised doctors and paramedical practitioners to report adverse reactions to medications and medical devices, and to not fear litigation. This advice followed the FDA noting that the country is one of the lowest-performing in terms of pharmacovigilance, because practitioners fear to become targets of lawsuits. Pharmacovigilance is defined by the World Health Organization as 'the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem', reports Inquirer.net.

In June 2014, the Philippine government identified India-based Medchem International as the company that manufactured an allegedly contaminated medicine,...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Philippines 2010-2018)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Philippines 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Philippines 2010-2018)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Philippines 2010-2018)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Philippines 2012-2018)
32
Table: Pharmaceutical Trade Data And Forecasts local currency (Philippines 2012-2018)
32
Other Healthcare Data
33
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
35
Economic Analysis
35
Investment To Continue Its Charge
35
Likely Recovery In The Export Sector
37
Typhoon Yolanda To Spur Public Spending
38
Remittances Supporting Private Consumption Growth
38
Risks To Economic Outlook
39
Table: Philippines - Economic Activity
40
Industry Risk Reward Ratings
41
Asia Risk/Reward Ratings
41
Philippines Risk/Reward Ratings
47
Rewards
47
Risks
47
Market Overview
49
Industry Trends And Developments
50
Epidemiology
50
Healthcare Sector
54
Health Insurance
58
Healthcare Sector Financing
61
Medical Tourism
61
Biotechnology And Research
62
Traditional Medicines
64
Clinical Trials
65
Regulatory Development
66
Table: History Of Food And Drugs Administration
67
Intellectual Property Regime
70
Pricing Regime
75
Table: Medicines Subject To March 31 2010 Government Mediated Access Price
79
Reimbursement Regime
80
International Cooperation
81
Competitive Landscape
84
Pharmaceutical Industry
84
Table: Pharmaceutical Industry Overview
84
Domestic Pharmaceutical Industry
84
Pharmaceutical Distribution and Retail
87
Table: Overview Of BnB, BNB and P100 Programme
92
Table: Cost Of Generic Drugs In Philippines (PHP)
92
Table: Number Of BnBs And BNBs In Selected Philippine Regions
93
Company Profile
94
Unilab
94
Pascual Laboratories
97
Pacific Pharmaceutical Generics
100
MediChem Pharmaceuticals
102
GlaxoSmithKline Philippines
104
Pfizer
107
Novartis
111
Merck & Co
116
Sanofi
118
Demographic Forecast
122
Demographic Outlook
122
Table: The Philippines' Population By Age Group, 1990-2020 ('000)
123
Table: The Philippines' Population By Age Group, 1990-2020 (% of total)
124
Table: The Philippines' Key Population Ratios, 1990-2020
125
Table: The Philippines' Rural And Urban Population, 1990-2020
125
Glossary
126
Methodology
128
Pharmaceutical Expenditure Forecast Model
128
Healthcare Expenditure Forecast Model
128
Notes On Methodology
129
Risk/Reward Ratings Methodology
130
Ratings Overview
131
Table: Pharmaceutical Risk/Reward Ratings Indicators
131
Indicator Weightings
132

The Philippines Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Philippines Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Philippine pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Philippines to test other views - a key input for successful budgeting and strategic business planning in the Philippine pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Philippine pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Philippines.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc